State Board of Administration of Florida Retirement System purchased a new stake in shares of REGENXBIO Inc. (NASDAQ:RGNX) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 9,965 shares of the biotechnology company’s stock, valued at approximately $328,000.
Several other hedge funds have also recently made changes to their positions in RGNX. Parametric Portfolio Associates LLC boosted its stake in shares of REGENXBIO by 169.3% during the first quarter. Parametric Portfolio Associates LLC now owns 40,928 shares of the biotechnology company’s stock valued at $790,000 after purchasing an additional 25,729 shares in the last quarter. American International Group Inc. lifted its stake in shares of REGENXBIO by 7.1% in the first quarter. American International Group Inc. now owns 12,468 shares of the biotechnology company’s stock worth $241,000 after acquiring an additional 822 shares during the period. Vanguard Group Inc. lifted its stake in shares of REGENXBIO by 23.2% in the first quarter. Vanguard Group Inc. now owns 981,517 shares of the biotechnology company’s stock worth $18,942,000 after acquiring an additional 184,700 shares during the period. Geode Capital Management LLC lifted its stake in shares of REGENXBIO by 3.6% in the first quarter. Geode Capital Management LLC now owns 171,346 shares of the biotechnology company’s stock worth $3,306,000 after acquiring an additional 5,949 shares during the period. Finally, Schwab Charles Investment Management Inc. lifted its stake in shares of REGENXBIO by 6.2% in the first quarter. Schwab Charles Investment Management Inc. now owns 73,724 shares of the biotechnology company’s stock worth $1,423,000 after acquiring an additional 4,275 shares during the period. 68.73% of the stock is currently owned by hedge funds and other institutional investors.
RGNX has been the topic of several recent analyst reports. Chardan Capital boosted their price target on REGENXBIO from $50.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, August 9th. Zacks Investment Research raised REGENXBIO from a “hold” rating to a “buy” rating and set a $23.00 price target on the stock in a research note on Saturday, August 12th. BidaskClub upgraded REGENXBIO from a “hold” rating to a “buy” rating in a report on Saturday, August 12th. Evercore ISI initiated coverage on REGENXBIO in a report on Wednesday, August 16th. They set an “outperform” rating and a $25.00 price objective for the company. Finally, Bank of America boosted their price objective on REGENXBIO from $29.00 to $33.00 and gave the company a “buy” rating in a report on Thursday, September 21st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $42.43.
Shares of REGENXBIO Inc. (NASDAQ:RGNX) traded up $1.25 during trading hours on Wednesday, reaching $29.45. The company’s stock had a trading volume of 198,943 shares, compared to its average volume of 277,735. REGENXBIO Inc. has a 52-week low of $16.30 and a 52-week high of $36.10.
REGENXBIO (NASDAQ:RGNX) last issued its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.67) EPS for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.04. REGENXBIO had a negative return on equity of 39.33% and a negative net margin of 764.06%. The firm had revenue of $1.34 million for the quarter. equities research analysts expect that REGENXBIO Inc. will post -2.71 earnings per share for the current fiscal year.
In related news, insider Kenneth T. Mills sold 10,000 shares of the stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $27.71, for a total transaction of $277,100.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Curran Simpson sold 2,000 shares of the company’s stock in a transaction dated Monday, November 27th. The stock was sold at an average price of $29.31, for a total value of $58,620.00. Following the completion of the transaction, the senior vice president now owns 41,500 shares in the company, valued at $1,216,365. The disclosure for this sale can be found here. Insiders have sold a total of 149,452 shares of company stock worth $4,441,270 in the last three months. 17.00% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION NOTICE: “State Board of Administration of Florida Retirement System Invests $328,000 in REGENXBIO Inc. (RGNX) Stock” was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://ledgergazette.com/2017/12/07/state-board-of-administration-of-florida-retirement-system-invests-328000-in-regenxbio-inc-rgnx-stock.html.
REGENXBIO Company Profile
REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.
Receive News & Ratings for REGENXBIO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.